Telesis Bio Performance
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Telesis Bio are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Telesis Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Telesis Bio is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 30.6 M |
Telesis |
Telesis Bio Relative Risk vs. Return Landscape
If you would invest (100.00) in Telesis Bio on December 19, 2024 and sell it today you would earn a total of 100.00 from holding Telesis Bio or generate -100.0% return on investment over 90 days. Telesis Bio is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Telesis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Telesis Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Telesis Bio's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Telesis Bio, and traders can use it to determine the average amount a Telesis Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| TBIO |
Based on monthly moving average Telesis Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Telesis Bio by adding Telesis Bio to a well-diversified portfolio.
Telesis Bio Fundamentals Growth
Telesis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Telesis Bio, and Telesis Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Telesis Pink Sheet performance.
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (2.53) % | ||||
| Operating Margin | (6.76) % | ||||
| Current Valuation | 61.1 M | ||||
| Shares Outstanding | 1.77 M | ||||
| Price To Earning | 71.32 X | ||||
| Price To Book | 1.11 X | ||||
| Price To Sales | 0.29 X | ||||
| Revenue | 27.51 M | ||||
| EBITDA | (31.05 M) | ||||
| Cash And Equivalents | 654.75 M | ||||
| Cash Per Share | 8.70 X | ||||
| Total Debt | 34.38 M | ||||
| Debt To Equity | 0.16 % | ||||
| Book Value Per Share | (11.59) X | ||||
| Cash Flow From Operations | (34.67 M) | ||||
| Earnings Per Share | (30.42) X | ||||
| Total Asset | 70.41 M | ||||
| Retained Earnings | (161.47 M) | ||||
| Current Asset | 3.28 M | ||||
| Current Liabilities | 16.98 M | ||||
Things to note about Telesis Bio performance evaluation
Checking the ongoing alerts about Telesis Bio for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Telesis Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Telesis Bio is not yet fully synchronised with the market data | |
| Telesis Bio has some characteristics of a very speculative penny stock | |
| Telesis Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 27.51 M. Net Loss for the year was (47.72 M) with profit before overhead, payroll, taxes, and interest of 15.6 M. | |
| Telesis Bio currently holds about 654.75 M in cash with (34.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.7. | |
| Roughly 38.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Telesis Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Telesis Bio's stock is overvalued or undervalued compared to its peers.
- Examining Telesis Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Telesis Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Telesis Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Telesis Bio's pink sheet. These opinions can provide insight into Telesis Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Telesis Pink Sheet
If you are still planning to invest in Telesis Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Telesis Bio's history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| CEOs Directory Screen CEOs from public companies around the world |